BioCentury
ARTICLE | Clinical News

Progenics recovers some of its losses

January 31, 2014 3:00 AM UTC

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) was up $0.70 (16%) to $5.20 on Thursday, recovering some of the company's losses on Wednesday after an abstract from the American Society of Clinical Oncology Genitourinary Cancers Symposium revealed two sepsis deaths in a Phase II trial of the company's PSMA ADC. On Thursday, Progenics presented data from that trial and provided more details on the deaths, along with data from a Phase II trial evaluating the company's 99mTc-MIP-1404 as a diagnostic for prostate cancer.

Progenics said the two deaths in the Phase II PSMA ADC 2301 trial were in metastatic castration-resistant prostate cancer (CRPC) patients with advanced disease who each received one cycle of 2.5 mg/kg IV PSMA ADC. The company said one of the patients had been hospitalized a couple of weeks prior to enrollment due to an infection that recurred. The other patient that died had an infection upon enrollment. Progenics said the deaths were due in part to a drop in white blood cell count as a result of treatment with PSMA ADC. The company said an independent DMB, the trial investigators and FDA agreed that the trial could move forward with a 2.3 mg/kg dose of PSMA ADC. Progenics also said it will now exclude patients with a serious infection within a month prior to enrollment. Progenics fell $1.70 (27%) to $4.50 on Wednesday after the deaths were revealed (see BioCentury Extra, Jan. 29). ...